Etrasimod

Unassigned

New Medicines

Ulcerative colitis

Information

New molecular entity
Arean
Arena

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selectively targets the sphingosine 1 phosphate type 1 (S1p1) receptor to reduce circulating lymphocytes by disrupting lymphocyte migration from the lymphoid organs into the blood. Fewer circulating lymphocytes are available to cause tissue damage.[2]
Ulcerative colitis is the most common type of inflammatory disease of the bowel. It has an incidence in the UK of approximately 10 per 100,000 people annually and a prevalence of approximately 240 per 100,000. Ulcerative colitis can develop at any age but peak incidence is between the ages of 15 and 25 years, with a second, smaller peak between 55 and 65 years [1].
Ulcerative colitis
Oral